Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials-Reference-Cited by-同舟云学术

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Published:2018-01 Issue:1 Volume:4 Page:234-242
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Gold Michael¹,Amatniek Joan²,Carrillo Maria C.³,Cedarbaum Jesse M.⁴,Hendrix James A.³,Miller Bradley B.⁵,Robillard Julie M.⁶,Rice J. Jeremy⁷,Soares Holly¹,Tome Maria B.⁸,Tarnanas Ioannis⁹¹⁰¹¹¹²,Vargas Gabriel¹³,Bain Lisa J.¹⁴,Czaja Sara J.¹⁵

Affiliation:

1. AbbVie Inc.North ChicagoIllinoisUSA

2. Otsuka Pharmaceutical Development & Commercialization, Inc.PrincetonNJUSA

3. Alzheimer's AssociationChicagoILUSA

4. BiogenCambridgeMAUSA

5. Eli Lilly and CompanyIndianapolisINUSA

6. Division of Neurology, Department of MedicineUniversity of British Columbia and Children's and Women's Hospital and Health CentresVancouverBCCanada

7. Healthcare and Life Science Research, IBM T.J. Watson Research CenterNew YorkNYUSA

8. European Medicines Agency (EMA)LondonUK

9. Altoida Inc.La JollaCAUSA

10. Scripps Memorial HospitalSan DiegoCAUSA

11. Atlantic Fellow for Equity in Brain Health with the Global Brain Health Institute (GBHI) at UCSFSan FranciscoCAUSA

12. Trinity College DublinDublinIreland

13. Early DevelopmentAmgenThousand OaksCAUSA

14. Independent Science WriterElversonPAUSA

15. Department of Psychiatry and Behavioral ScienceMiller School of Medicine, University of MiamiMiamiFLUSA

Publisher

Wiley

Subject